ImmunityBio IncIBRX
Price$9.28

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $165.8M+1,024.4% YoYTTM through 30 Jun 2026
Net Income -$992.4MTTM through 30 Jun 2026
Free Cash Flow -$288.1MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-141.9%
Operating Margin-151.9%
Net Margin-598.6%

Returns

94.8%ROE
-132.0%ROA

Balance Sheet Health

Debt / Equity-1.29x
Current Ratio5.10x
Net Debt$739.1M
Cash & Equivalents$75.7M

Quality Metrics

Altman Z-Score-7.06
Piotroski F-Score2 / 9
FCF Margin-173.8%
Rule of 40-137.6
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $113.3M
Diluted EPS-$0.95TTM
'19'20'21'22'23'24'25
FY2025: $-0.38

Dividend

No dividend

Capital Allocation

Capex Intensity4.2%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.